NEW YORK, May 31 (Reuters) - Biopharmaceutical firm Jazz Pharmaceuticals on Thursday raised $108 million in an initial public offering that priced below a reduced forecast range.
The 6-million-share offering priced at $18 compared with a forecast range of $20 to $21, according to an underwriter.
The forecast range was initially $24 to $26 before being cut earlier on Thursday, according to an amended filing with the U.S. Securities and Exchange Commission.
Underwriters, led by Morgan Stanley and Lehman, have the option to purchase an additional 900,000 shares to cover overallotments.
The company plans to list its shares on the Nasdaq under the symbol "JAZZ." JAZZ.O.
Our Standards: The Thomson Reuters Trust Principles.